AU2010229705A1 - Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination - Google Patents

Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination Download PDF

Info

Publication number
AU2010229705A1
AU2010229705A1 AU2010229705A AU2010229705A AU2010229705A1 AU 2010229705 A1 AU2010229705 A1 AU 2010229705A1 AU 2010229705 A AU2010229705 A AU 2010229705A AU 2010229705 A AU2010229705 A AU 2010229705A AU 2010229705 A1 AU2010229705 A1 AU 2010229705A1
Authority
AU
Australia
Prior art keywords
seq
vegf
antibody
cancer
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010229705A
Other languages
English (en)
Inventor
Carl W. Birks
Qi Pan
Pallavur V. Sivakumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of AU2010229705A1 publication Critical patent/AU2010229705A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010229705A 2009-03-27 2010-03-26 Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination Abandoned AU2010229705A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16402309P 2009-03-27 2009-03-27
US61/164,023 2009-03-27
PCT/US2010/028877 WO2010111625A1 (en) 2009-03-27 2010-03-26 Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination

Publications (1)

Publication Number Publication Date
AU2010229705A1 true AU2010229705A1 (en) 2011-10-20

Family

ID=42332479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010229705A Abandoned AU2010229705A1 (en) 2009-03-27 2010-03-26 Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination

Country Status (8)

Country Link
US (1) US20120134993A1 (cg-RX-API-DMAC7.html)
EP (1) EP2411407A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012521768A (cg-RX-API-DMAC7.html)
KR (1) KR20110134494A (cg-RX-API-DMAC7.html)
CN (1) CN102448984A (cg-RX-API-DMAC7.html)
AU (1) AU2010229705A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011009810A (cg-RX-API-DMAC7.html)
WO (1) WO2010111625A1 (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
HK1219533A1 (zh) * 2013-03-15 2017-04-07 Intermune, Inc. 蛋白质组学ipf标志物
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US9920096B2 (en) 2013-06-25 2018-03-20 Sepia Pesquisa E Desenvolvimento Bradykinin receptor modulators and use thereof
KR102060187B1 (ko) 2013-07-19 2019-12-27 삼성전자주식회사 Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
LT3041513T (lt) 2013-09-08 2020-11-25 Kodiak Sciences Inc. Viii faktoriaus cviterioninių polimerų konjugatai
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2015200905A2 (en) * 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
CN104177492B (zh) * 2014-07-21 2017-02-22 暨南大学 FGFR2c胞外段类似物及其编码基因与应用
EA037920B1 (ru) 2014-09-26 2021-06-07 Янссен Фармацевтика Нв Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
KR102548827B1 (ko) * 2014-12-22 2023-06-30 시스트이뮨, 인코포레이티드 이중특이적 4가 항체 및 이의 제조 및 사용방법
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
EA201890305A1 (ru) 2015-07-15 2018-07-31 Генмаб А/С Гуманизированные или химерные cd3-антитела
AU2016363668A1 (en) * 2015-11-30 2018-05-24 Pieris Australia Pty Ltd. Novel anti-angiogenic fusion polypeptides
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR20240017129A (ko) 2016-07-14 2024-02-06 젠맵 에이/에스 Cd40 및 cd137에 대한 다중특이적 항체
PL3592769T3 (pl) 2017-03-09 2024-10-14 Genmab A/S Przeciwciała przeciwko PD-L1
IL269645B2 (en) 2017-03-31 2025-05-01 Genmab Holding B V Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN113260629A (zh) 2018-09-19 2021-08-13 拉法医疗有限公司 用于治疗恶性血液病的新双特异性抗体
WO2020070313A1 (en) 2018-10-04 2020-04-09 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
WO2020094744A1 (en) 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
CN113993893A (zh) 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
JPWO2021010326A1 (cg-RX-API-DMAC7.html) * 2019-07-12 2021-01-21
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
AU2021236906A1 (en) 2020-03-18 2022-08-18 Genmab A/S Antibodies binding to B7H4
JP2023524149A (ja) 2020-05-08 2023-06-08 ジェンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
US20230287088A1 (en) 2020-08-06 2023-09-14 BioNTech SE Binding agents for coronavirus s protein
BR112023004321A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma de célula b grande difusa em um sujeito humano
JP2023541858A (ja) 2020-09-10 2023-10-04 ジェンマブ エー／エス 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体
KR20230157933A (ko) 2020-12-10 2023-11-17 라바 테라퓨틱스 엔.브이. 감마-델타 t 세포 수용체에 결합하는 항체
CA3209454A1 (en) 2021-02-26 2022-09-01 Robertus Cornelis ROOVERS Antibodies that bind cd123 and gamma-delta t cell receptors
IL308300A (en) 2021-05-07 2024-01-01 Genmab As PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3
IL309319A (en) 2021-06-21 2024-02-01 Genmab As Combined dosage regimen CD137 and PD-L1 binding agents
AU2022344595A1 (en) 2021-09-13 2024-05-02 Janssen Biotech, Inc CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
WO2023057571A1 (en) 2021-10-08 2023-04-13 Genmab A/S Antibodies binding to cd30 and cd3
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
NL2032398B1 (en) 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
CN116199744B (zh) * 2023-03-23 2024-06-25 湖南中晟全肽生物科技股份有限公司 一种结合fgfr2受体的多肽及其用途
EP4438624A1 (en) 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
WO2024208898A1 (en) 2023-04-05 2024-10-10 Genmab A/S Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
JP2025530208A (ja) 2023-06-30 2025-09-11 ジェンマブ エー／エス 線維芽細胞活性化タンパク質アルファおよびデスレセプター４に結合する抗体
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
TW202519261A (zh) 2023-07-27 2025-05-16 荷蘭商拉法醫療公司 用於治療癌症之結合γ-δ T細胞受體之抗體
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083704A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
AU2002339863A1 (en) * 2001-08-31 2003-03-18 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
US8124085B2 (en) * 2004-05-05 2012-02-28 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US7678890B2 (en) * 2005-07-22 2010-03-16 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
JP6035009B2 (ja) * 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
WO2009120922A2 (en) * 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a

Also Published As

Publication number Publication date
MX2011009810A (es) 2011-09-30
WO2010111625A1 (en) 2010-09-30
KR20110134494A (ko) 2011-12-14
CN102448984A (zh) 2012-05-09
US20120134993A1 (en) 2012-05-31
JP2012521768A (ja) 2012-09-20
EP2411407A1 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
US20120134993A1 (en) Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
AU2009228158B2 (en) Compositions and methods for inhibiting PDGFRbeta and VEGF-A
JP7397105B2 (ja) 二重特異性ＥＧＦＲ／ｃ－Ｍｅｔ抗体
KR101862832B1 (ko) Ｐａｎ―ｈｅｒ 항체 조성물
US20110081345A1 (en) Single chain fc, methods of making and methods of treatment
US20090053241A1 (en) PDGFRbeta-specific inhibitors
EP4644425A1 (en) Antibody that binds ErbB-2 and ErbB-3
KR20230132544A (ko) 신규한 항-그렘린1 항체
EP2985292A1 (en) Epidermal growth factor receptor antibody
CN120239710A (zh) 抗ccr8抗体及其用途
KR20230142768A (ko) Ccdc112를 기반으로 하는 종양세포 성장을 억제하는 방법 및 적용
CN114729048A (zh) 使用抗ox40抗体与tlr激动剂组合治疗癌症的方法
WO2025067442A1 (zh) 抗fgfr2抗体和包含其的多特异性结合分子
WO2025025434A1 (zh) EGFR/c-Met双特异性抗体及其应用
EA039356B1 (ru) БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application